Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
Year: 2023
Type: article
Abstract: To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patients' prognosis worsens after relapse, and the disease burden and drug toxicities are generally more challenging with subsequent lines of therapy. It is therefore particularly important that patients with newly diagnosed multiple myeloma (NDMM) receive optimal frontline therapy. The combination of lenalidomide, bortezomib, and dexamethasone (RVd) has consistently demonstrated a tolerable safety profile with significant and clinically relevant benefit, including deep and durable responses with improved survival in patients with NDMM regardless of their transplant eligibility. Furthermore, comparative studies evaluating this triplet regimen against both doublet and other triplet regimens have established RVd as a standard of care in this setting based upon its remarkable and concordant efficacy. Given the breadth of clinical data, physician familiarity, inclusion in treatment guidelines, and the emerging potential of RVd-containing quadruplet regimens, RVd will likely continue as a key cornerstone of the treatment of NDMM, and its role will therefore likely continue to grow as a therapeutic backbone in the initial treatment of MM.
Source: Haematologica
Authors: Paul G. Richardson, Brian G. Durie, Laura Rosiñol, Maria-Victoria Mateos, Angela Dispenzieri, Philippe Moreau, Shaji Kumar, Noopur Raje, Nikhil Munshi, Jacob P. Laubach, Peter O’Gorman, Elizabeth O’Donnell, Peter Voorhees, Thierry Facon, Joan Bladé, Sagar Lonial, Aurore Perrot, Kenneth C. Anderson
Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Cedars-Sinai Medical Center, Hospital Clínic de Barcelona, Universitat de Barcelona, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer de Salamanca, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), Centre Hospitalier Universitaire de Nantes, Massachusetts General Hospital, University College Dublin, Mater Misericordiae University Hospital, Levine Cancer Institute, Université de Lille, Centre Hospitalier Universitaire de Lille, Emory University, Winship Cancer Institute, Institut universitaire du cancer de Toulouse Oncopole
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
Award: G1016754749
OpenAlex ID: W4386083642